{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,25]],"date-time":"2026-08-25T09:22:10Z","timestamp":1787649730195,"version":"build-2736575974"},"reference-count":136,"publisher":"Walter de Gruyter GmbH","license":[{"start":{"date-parts":[[2026,8,26]],"date-time":"2026-08-26T00:00:00Z","timestamp":1787702400000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100018973","name":"Lovely Professional University","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100018973","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec id=\"j_dmdi-2026-0021_abs_001\">\n                    <jats:title>Introduction<\/jats:title>\n                    <jats:p>Neuropathic pain is a chronic and debilitating condition characterized by maladaptive changes in peripheral and central nervous system pathways. It is driven by abnormal neuronal excitability and excitatory neurotransmission. Among the key contributors are voltage-gated sodium channels (VGSCs) and glutamatergic mechanisms, both of which play pivotal roles in peripheral and central sensitization.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"j_dmdi-2026-0021_abs_002\">\n                    <jats:title>Content<\/jats:title>\n                    <jats:p>\n                      This narrative review was conducted through a structured literature search of PubMed\/MEDLINE, Embase, Web of Science, Scopus,\n                      <jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"uri\" xlink:href=\"http:\/\/ClinicalTrials.gov\">ClinicalTrials.gov<\/jats:ext-link>\n                      , Google Scholar, and relevant gray literature sources. Search terms included safinamide, Xadago, sodium channels, Nav1.7, Nav1.8, glutamate, NMDA, AMPA, mGluR, EAAT, neuropathic pain, and neuropathy. English-language\n                      <jats:italic>in\u00a0vitro<\/jats:italic>\n                      , animal, and human studies were considered, and evidence was synthesized according to mechanistic relevance, preclinical findings, clinical pain outcomes, and translational limitations.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"j_dmdi-2026-0021_abs_003\">\n                    <jats:title>Summary<\/jats:title>\n                    <jats:p>Through selective interaction with inactivated sodium channel states that are common in hyperexcitable neurons and presynaptic regulation of glutamate without interfering with normal transmission. Safinamide is able to suppress ectopic discharges, decrease central sensitization, and alleviate neuroinflammation. Preclinical models reveal the strong dose-dependent antinociceptive activity, the restoration of sodium current densities, and the decreased evoked glutamate overflow. There are clinical studies of the populations with the PD that demonstrate that pain-related outcomes improve significantly and depend on the improvement of motor symptoms to a lesser extent. Safinamide\u2019s balanced profile has the potential benefits of improved tolerability and multimodal activity compared to conventional sodium channel blockers or direct NMDA antagonists.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"j_dmdi-2026-0021_abs_004\">\n                    <jats:title>Outlook<\/jats:title>\n                    <jats:p>Although the existing clinical evidence outside the context of Parkinson\u2019s disease is still scarce, its pharmacodynamic characteristics make it possible to develop further studies in a variety of neuropathic pain syndromes using biomarker-based, randomized controlled trials.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1515\/dmpt-2026-0021","type":"journal-article","created":{"date-parts":[[2026,8,25]],"date-time":"2026-08-25T08:57:38Z","timestamp":1787648258000},"source":"Crossref","is-referenced-by-count":0,"title":["Safinamide dual molecular mechanisms: sodium channel and glutamate modulation as a translational rationale for neuropathic pain\u00a0\u2013\u00a0A narrative review"],"prefix":"10.1515","author":[{"ORCID":"https:\/\/orcid.org\/0009-0006-9347-9437","authenticated-orcid":false,"given":"Utpal","family":"Bhui","sequence":"first","affiliation":[{"name":"Department of Pharmacology , School of Pharmaceutical Sciences, Lovely Professional University , Phagwara , Punjab , India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Radheshyam","family":"Pal","sequence":"additional","affiliation":[{"name":"Department of Pharmacology , School of Pharmaceutical Sciences, Lovely Professional University , Phagwara , Punjab , India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amit","family":"Chakraborty","sequence":"additional","affiliation":[{"name":"Department of Bioengineering , Clemson University , Clemson , SC , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sathvik Belagodu","family":"Sridhar","sequence":"additional","affiliation":[{"name":"College of Pharmacy , Dubai Medical University , Dubai , UAE"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Uttam Prasad","family":"Panigrahy","sequence":"additional","affiliation":[{"name":"Jeypore College of Pharmacy , Rondapalli , Jeypore, Koraput , Odisha , India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shubhrajit","family":"Mantry","sequence":"additional","affiliation":[{"name":"Department of Pharmacy , Sarala Birla University Birla , Ranchi , Jharkhand , India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bimlesh","family":"Kumar","sequence":"additional","affiliation":[{"name":"Department of Pharmacology , School of Pharmaceutical Sciences, Lovely Professional University , Phagwara , Punjab , India"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"374","published-online":{"date-parts":[[2026,8,26]]},"reference":[{"key":"2026082508572973721_j_dmdi-2026-0021_ref_001","doi-asserted-by":"crossref","unstructured":"Van Hecke, O, Austin, SK, Khan, RA, Smith, BH, Torrance, N. Neuropathic pain in the general population: a systematic review of epidemiological studies. Pain 2014;155:654\u201362. https:\/\/doi.org\/10.1016\/j.pain.2013.11.013.","DOI":"10.1016\/j.pain.2013.11.013"},{"key":"2026082508572973721_j_dmdi-2026-0021_ref_002","doi-asserted-by":"crossref","unstructured":"Baskozos, G, H\u00e9bert, HL, Pascal, MM, Themistocleous, AC, Macfarlane, GJ, Wynick, D, et al.. Epidemiology of neuropathic pain: an analysis of prevalence and associated factors in UK Biobank. Pain Rep 2023;8:e1066. https:\/\/doi.org\/10.1097\/pr9.0000000000001066.","DOI":"10.1097\/PR9.0000000000001066"},{"key":"2026082508572973721_j_dmdi-2026-0021_ref_003","doi-asserted-by":"crossref","unstructured":"Finnerup, NB, Haroutounian, S, Kamerman, P, Baron, R, Bennett, DL, Bouhassira, D, et al.. Neuropathic pain: an updated grading system for research and clinical practice. Pain 2016;157:1599\u2013606. https:\/\/doi.org\/10.1097\/j.pain.0000000000000492.","DOI":"10.1097\/j.pain.0000000000000492"},{"key":"2026082508572973721_j_dmdi-2026-0021_ref_004","doi-asserted-by":"crossref","unstructured":"Zilliox, LA. Neuropathic pain. Continuum 2017;23:512\u201332. https:\/\/doi.org\/10.1212\/con.0000000000000462.","DOI":"10.1212\/CON.0000000000000462"},{"key":"2026082508572973721_j_dmdi-2026-0021_ref_005","doi-asserted-by":"crossref","unstructured":"Bouhassira, D, Attal, N, Alchaar, H, Boureau, F, Brochet, B, Bruxelle, J, et al.. Comparison of pain syndromes associated with nervous or somatic lesions and development of a new neuropathic pain diagnostic questionnaire (DN4). Pain 2005;114:29\u201336. https:\/\/doi.org\/10.1016\/j.pain.2004.12.010.","DOI":"10.1016\/j.pain.2004.12.010"},{"key":"2026082508572973721_j_dmdi-2026-0021_ref_006","doi-asserted-by":"crossref","unstructured":"Bennett, M. The LANSS pain scale: the Leeds assessment of neuropathic symptoms and signs. Pain 2001;92:147\u201357. https:\/\/doi.org\/10.1016\/s0304-3959(00)00482-6.","DOI":"10.1016\/S0304-3959(00)00482-6"},{"key":"2026082508572973721_j_dmdi-2026-0021_ref_007","doi-asserted-by":"crossref","unstructured":"Bennett, M. The LANSS pain scale: the Leeds assessment of neuropathic symptoms and signs. Pain Pract 2001;1:379.","DOI":"10.1037\/t19515-000"},{"key":"2026082508572973721_j_dmdi-2026-0021_ref_008","doi-asserted-by":"crossref","unstructured":"Freynhagen, R, Baron, R, Gockel, U, T\u00f6lle, TR. painDETECT: a new screening questionnaire to identify neuropathic components in patients with back pain. Curr Med Res Opin 2006;22:1911\u201320. https:\/\/doi.org\/10.1185\/030079906x132488.","DOI":"10.1185\/030079906X132488"},{"key":"2026082508572973721_j_dmdi-2026-0021_ref_009","doi-asserted-by":"crossref","unstructured":"Scholz, J, Finnerup, NB, Attal, N, Aziz, Q, Baron, R, Bennett, MI, et al.. The IASP classification of chronic pain for ICD-11: chronic neuropathic pain. Pain 2019;160:53\u20139. https:\/\/doi.org\/10.1097\/j.pain.0000000000001365.","DOI":"10.1097\/j.pain.0000000000001365"},{"key":"2026082508572973721_j_dmdi-2026-0021_ref_010","unstructured":"Rai, SN, editor. Neurobiology of aging: exploring cognitive decline and neurodegeneration. Academic Press; 2025."},{"key":"2026082508572973721_j_dmdi-2026-0021_ref_011","doi-asserted-by":"crossref","unstructured":"Rajamanickam, K. Multimodal molecular imaging strategies using functionalized nano probes. J\u00a0Nanotechnol Res 2019;1:119\u201335. https:\/\/doi.org\/10.26502\/jnr.2688-85210010.","DOI":"10.26502\/jnr.2688-85210010"},{"key":"2026082508572973721_j_dmdi-2026-0021_ref_012","doi-asserted-by":"crossref","unstructured":"Dwivedi, DK, Jagannathan, NR. Emerging MR methods for improved diagnosis of prostate cancer by multiparametric MRI. MAGMA 2022;35:587\u2013608. https:\/\/doi.org\/10.1007\/s10334-022-01031-5.","DOI":"10.1007\/s10334-022-01031-5"},{"key":"2026082508572973721_j_dmdi-2026-0021_ref_013","doi-asserted-by":"crossref","unstructured":"Felix, R, Corzo-Lopez, A, Sandoval, A. Voltage-gated ion channels in neuropathic pain signaling. Life 2025;15:888. https:\/\/doi.org\/10.3390\/life15060888.","DOI":"10.3390\/life15060888"},{"key":"2026082508572973721_j_dmdi-2026-0021_ref_014","doi-asserted-by":"crossref","unstructured":"Devor, M. Sodium channels and mechanisms of neuropathic pain. J\u00a0Pain 2006;7:S3\u201312. https:\/\/doi.org\/10.1016\/j.jpain.2005.09.006.","DOI":"10.1016\/j.jpain.2005.09.006"},{"key":"2026082508572973721_j_dmdi-2026-0021_ref_015","doi-asserted-by":"crossref","unstructured":"Aurilio, C, Pota, V, Pace, MC, Passavanti, MB, Barbarisi, M. Ionic channels and neuropathic pain: physiopathology and applications. J\u00a0Cell Physiol 2008;215:8\u201314. https:\/\/doi.org\/10.1002\/jcp.21280.","DOI":"10.1002\/jcp.21280"},{"key":"2026082508572973721_j_dmdi-2026-0021_ref_016","doi-asserted-by":"crossref","unstructured":"Gracely, RH, Lynch, SA, Bennett, GJ. Painful neuropathy: altered central processing maintained dynamically by peripheral input. Pain 1992;51:175\u201394. https:\/\/doi.org\/10.1016\/0304-3959(92)90259-e.","DOI":"10.1016\/0304-3959(92)90259-E"},{"key":"2026082508572973721_j_dmdi-2026-0021_ref_017","doi-asserted-by":"crossref","unstructured":"Hoffmann, T, Sharon, O, Wittmann, J, Carr, RW, Vyshnevska, A, De Col, R, et al.. NaV1.7 and pain: contribution of peripheral nerves. Pain 2018;159:496\u2013506. https:\/\/doi.org\/10.1097\/j.pain.0000000000001119.","DOI":"10.1097\/j.pain.0000000000001119"},{"key":"2026082508572973721_j_dmdi-2026-0021_ref_018","doi-asserted-by":"crossref","unstructured":"Hains, BC, Klein, JP, Saab, CY, Craner, MJ, Black, JA, Waxman, SG. Upregulation of sodium channel Nav1.3 and functional involvement in neuronal hyperexcitability associated with central neuropathic pain after spinal cord injury. J\u00a0Neurosci 2003;23:8881\u201392. https:\/\/doi.org\/10.1523\/jneurosci.23-26-08881.2003.","DOI":"10.1523\/JNEUROSCI.23-26-08881.2003"},{"key":"2026082508572973721_j_dmdi-2026-0021_ref_019","doi-asserted-by":"crossref","unstructured":"Alsaloum, M, Labau, JI, Liu, S, Estacion, M, Zhao, P, Dib-Hajj, F, et al.. Contributions of NaV1.8 and NaV1.9 to excitability in human induced pluripotent stem-cell derived somatosensory neurons. Sci Rep 2021;11:24283. https:\/\/doi.org\/10.1038\/s41598-021-03608-x.","DOI":"10.1038\/s41598-021-03608-x"},{"key":"2026082508572973721_j_dmdi-2026-0021_ref_020","doi-asserted-by":"crossref","unstructured":"Tsantoulas, C, McMahon, SB. Opening paths to novel analgesics: the role of potassium channels in chronic pain. Trends Neurosci 2014;37:146\u201358. https:\/\/doi.org\/10.1016\/j.tins.2013.12.002.","DOI":"10.1016\/j.tins.2013.12.002"},{"key":"2026082508572973721_j_dmdi-2026-0021_ref_021","doi-asserted-by":"crossref","unstructured":"Rasband, MN, Park, EW, Vanderah, TW, Lai, J, Porreca, F, Trimmer, JS. Distinct potassium channels on pain-sensing neurons. Proc Natl Acad Sci U S A 2001;98:13373\u20138. https:\/\/doi.org\/10.1073\/pnas.231376298.","DOI":"10.1073\/pnas.231376298"},{"key":"2026082508572973721_j_dmdi-2026-0021_ref_022","doi-asserted-by":"crossref","unstructured":"Busserolles, J, Tsantoulas, C, Eschalier, A, L\u00f3pez Garc\u00eda, JA. Potassium channels in neuropathic pain: advances, challenges, and emerging ideas. Pain 2016;157:S7\u201314. https:\/\/doi.org\/10.1097\/j.pain.0000000000000368.","DOI":"10.1097\/j.pain.0000000000000368"},{"key":"2026082508572973721_j_dmdi-2026-0021_ref_023","doi-asserted-by":"crossref","unstructured":"Tsantoulas, C. Emerging potassium channel targets for the treatment of pain. Curr Opin Support Palliat Care 2015;9:147\u201354. https:\/\/doi.org\/10.1097\/spc.0000000000000131.","DOI":"10.1097\/SPC.0000000000000131"},{"key":"2026082508572973721_j_dmdi-2026-0021_ref_024","doi-asserted-by":"crossref","unstructured":"Kuo, YL, Cheng, JK, Hou, WH, Chang, YC, Du, PH, Jian, JJ, et al.. K+ channel modulatory subunits KChIP and DPP participate in Kv4-mediated mechanical pain control. J\u00a0Neurosci 2017;37:4391\u2013404. https:\/\/doi.org\/10.1523\/jneurosci.1619-16.2017.","DOI":"10.1523\/JNEUROSCI.1619-16.2017"},{"key":"2026082508572973721_j_dmdi-2026-0021_ref_025","doi-asserted-by":"crossref","unstructured":"Kahle, KT, Staley, KJ, Nahed, BV, Gamba, G, Hebert, SC, Lifton, RP, et al.. Roles of the cation-chloride cotransporters in neurological disease. Nat Clin Pract Neurol 2008;4:490\u2013503. https:\/\/doi.org\/10.1038\/ncpneuro0883.","DOI":"10.1038\/ncpneuro0883"},{"key":"2026082508572973721_j_dmdi-2026-0021_ref_026","doi-asserted-by":"crossref","unstructured":"Li, L, Chen, SR, Chen, H, Wen, L, Hittelman, WN, Xie, JD, et al.. Chloride homeostasis critically regulates synaptic NMDA receptor activity in neuropathic pain. Cell Rep 2016;15:1376\u201383. https:\/\/doi.org\/10.1016\/j.celrep.2016.04.039.","DOI":"10.1016\/j.celrep.2016.04.039"},{"key":"2026082508572973721_j_dmdi-2026-0021_ref_027","doi-asserted-by":"crossref","unstructured":"Jentsch, TJ, Pusch, M. CLC chloride channels and transporters: structure, function, physiology, and disease. Physiol Rev 2018;98:1493\u2013590. https:\/\/doi.org\/10.1152\/physrev.00047.2017.","DOI":"10.1152\/physrev.00047.2017"},{"key":"2026082508572973721_j_dmdi-2026-0021_ref_028","doi-asserted-by":"crossref","unstructured":"Sun, W, Chen, C. Roles of proton-sensing receptors in the transition from acute to chronic pain. J\u00a0Dent Res 2016;95:135\u201342. https:\/\/doi.org\/10.1177\/0022034515618382.","DOI":"10.1177\/0022034515618382"},{"key":"2026082508572973721_j_dmdi-2026-0021_ref_029","doi-asserted-by":"crossref","unstructured":"Osikowicz, M, Mika, J, Przewlocka, B. The glutamatergic system as a target for neuropathic pain relief. Exp Physiol 2013;98:372\u201384. https:\/\/doi.org\/10.1113\/expphysiol.2012.069922.","DOI":"10.1113\/expphysiol.2012.069922"},{"key":"2026082508572973721_j_dmdi-2026-0021_ref_030","doi-asserted-by":"crossref","unstructured":"Chen, Z, He, Y, Wang, ZJ. The beta-lactam antibiotic, ceftriaxone, inhibits the development of opioid-induced hyperalgesia in mice. Neurosci Lett 2012;509:69\u201371. https:\/\/doi.org\/10.1016\/j.neulet.2011.12.029.","DOI":"10.1016\/j.neulet.2011.12.029"},{"key":"2026082508572973721_j_dmdi-2026-0021_ref_031","doi-asserted-by":"crossref","unstructured":"Dib-Hajj, SD, Yang, Y, Black, JA, Waxman, SG. The NaV1.7 sodium channel: from molecule to man. Nat Rev Neurosci 2013;14:49\u201362. https:\/\/doi.org\/10.1038\/nrn3404.","DOI":"10.1038\/nrn3404"},{"key":"2026082508572973721_j_dmdi-2026-0021_ref_032","doi-asserted-by":"crossref","unstructured":"Kerr, BJ, Souslova, V, McMahon, SB, Wood, JN. A role for the TTX-resistant sodium channel Nav1.8 in NGF-induced hyperalgesia, but not neuropathic pain. Neuroreport 2001;12:3077\u201380. https:\/\/doi.org\/10.1097\/00001756-200110080-00019.","DOI":"10.1097\/00001756-200110080-00019"},{"key":"2026082508572973721_j_dmdi-2026-0021_ref_033","doi-asserted-by":"crossref","unstructured":"Smith, ESJ, Momin, A. Persistent pain: the contribution of NaV1.9. J\u00a0Physiol 2008;586:2249. https:\/\/doi.org\/10.1113\/jphysiol.2008.152520.","DOI":"10.1113\/jphysiol.2008.152520"},{"key":"2026082508572973721_j_dmdi-2026-0021_ref_034","doi-asserted-by":"crossref","unstructured":"Ma, RSY, Kayani, K, Whyte-Oshodi, D, Whyte-Oshodi, A, Nachiappan, N, Gnanarajah, S, et al.. Voltage gated sodium channels as therapeutic targets for chronic pain. J\u00a0Pain Res 2019;12:2709\u201322. https:\/\/doi.org\/10.2147\/jpr.s207610.","DOI":"10.2147\/JPR.S207610"},{"key":"2026082508572973721_j_dmdi-2026-0021_ref_035","doi-asserted-by":"crossref","unstructured":"Dib-Hajj, SD, Waxman, SG. Sodium channels in human pain disorders: genetics and pharmacogenomics. Annu Rev Neurosci 2019;42:87\u2013106. https:\/\/doi.org\/10.1146\/annurev-neuro-070918-050144.","DOI":"10.1146\/annurev-neuro-070918-050144"},{"key":"2026082508572973721_j_dmdi-2026-0021_ref_036","doi-asserted-by":"crossref","unstructured":"Goodwin, G, McMahon, SB. The physiological function of different voltage-gated sodium channels in pain. Nat Rev Neurosci 2021;22:263\u201374. https:\/\/doi.org\/10.1038\/s41583-021-00444-w.","DOI":"10.1038\/s41583-021-00444-w"},{"key":"2026082508572973721_j_dmdi-2026-0021_ref_037","doi-asserted-by":"crossref","unstructured":"Larsson, M, Broman, J. Synaptic plasticity and pain: role of ionotropic glutamate receptors. Neuroscientist 2011;17:256\u201373. https:\/\/doi.org\/10.1177\/1073858409349913.","DOI":"10.1177\/1073858409349913"},{"key":"2026082508572973721_j_dmdi-2026-0021_ref_038","doi-asserted-by":"crossref","unstructured":"Sibarov, D, Antonov, S. Calcium-dependent desensitization of NMDA receptors. Biochemistry 2018;83:1173\u201383. https:\/\/doi.org\/10.1134\/s0006297918100036.","DOI":"10.1134\/S0006297918100036"},{"key":"2026082508572973721_j_dmdi-2026-0021_ref_039","doi-asserted-by":"crossref","unstructured":"Crown, ED, Ye, Z, Johnson, KM, Xu, GY, McAdoo, DJ, Westlund, KN, et al.. Upregulation of the phosphorylated form of CREB in spinothalamic tract cells following spinal cord injury: relation to central neuropathic pain. Neurosci Lett 2005;384:139\u201344. https:\/\/doi.org\/10.1016\/j.neulet.2005.04.066.","DOI":"10.1016\/j.neulet.2005.04.066"},{"key":"2026082508572973721_j_dmdi-2026-0021_ref_040","doi-asserted-by":"crossref","unstructured":"Latremoliere, A, Woolf, CJ. Central sensitization: a generator of pain hypersensitivity by central neural plasticity. J\u00a0Pain 2009;10:895\u2013926. https:\/\/doi.org\/10.1016\/j.jpain.2009.06.012.","DOI":"10.1016\/j.jpain.2009.06.012"},{"key":"2026082508572973721_j_dmdi-2026-0021_ref_041","doi-asserted-by":"crossref","unstructured":"Rai, SN. Recent advances in the treatment of neurodegenerative disorders. Bentham Science Publishers; 2021.","DOI":"10.2174\/97816810877261210101"},{"key":"2026082508572973721_j_dmdi-2026-0021_ref_042","doi-asserted-by":"crossref","unstructured":"Deng, M, Chen, SR, Pan, HL. Presynaptic NMDA receptors control nociceptive transmission at the spinal cord level in neuropathic pain. Cell Mol Life Sci 2019;76:1889\u201399. https:\/\/doi.org\/10.1007\/s00018-019-03047-y.","DOI":"10.1007\/s00018-019-03047-y"},{"key":"2026082508572973721_j_dmdi-2026-0021_ref_043","doi-asserted-by":"crossref","unstructured":"Waxman, SG, Merkies, ISJ, Gerrits, MM, Dib-Hajj, SD, Lauria, G, Cox, JJ, et al.. Sodium channel genes in pain-related disorders: phenotype-genotype associations and recommendations for clinical use. Lancet Neurol 2014;13:1152\u201360. https:\/\/doi.org\/10.1016\/s1474-4422(14)70150-4.","DOI":"10.1016\/S1474-4422(14)70150-4"},{"key":"2026082508572973721_j_dmdi-2026-0021_ref_044","doi-asserted-by":"crossref","unstructured":"McNearney, T, Baethge, BA, Cao, S, Alam, R, Lisse, JR, Westlund, KN. Excitatory amino acids, TNF-\u03b1, and chemokine levels in synovial fluids of patients with active arthropathies. Clin Exp Immunol 2004;137:621\u20137. https:\/\/doi.org\/10.1111\/j.1365-2249.2004.02563.x.","DOI":"10.1111\/j.1365-2249.2004.02563.x"},{"key":"2026082508572973721_j_dmdi-2026-0021_ref_045","doi-asserted-by":"crossref","unstructured":"Harris, RE, Napadow, V, Huggins, JP, Pauer, L, Kim, J, Hampson, J, et al.. Pregabalin rectifies aberrant brain chemistry, connectivity, and functional response in chronic pain patients. Anesthesiology 2013;119:1453\u201364. https:\/\/doi.org\/10.1097\/aln.0000000000000017.","DOI":"10.1097\/ALN.0000000000000017"},{"key":"2026082508572973721_j_dmdi-2026-0021_ref_046","doi-asserted-by":"crossref","unstructured":"M\u00fcller, T. Safinamide: an add-on treatment for managing Parkinson\u2019s disease. Clin Pharmacol 2018;10:31\u201341. https:\/\/doi.org\/10.2147\/cpaa.s137740.","DOI":"10.2147\/CPAA.S137740"},{"key":"2026082508572973721_j_dmdi-2026-0021_ref_047","doi-asserted-by":"crossref","unstructured":"Cattaneo, C, Kulisevsky, J, Tubazio, V, Castellani, P. Long-term efficacy of safinamide on Parkinson\u2019s disease chronic pain. Adv Ther 2018;35:515\u201322. https:\/\/doi.org\/10.1007\/s12325-018-0687-z.","DOI":"10.1007\/s12325-018-0687-z"},{"key":"2026082508572973721_j_dmdi-2026-0021_ref_048","doi-asserted-by":"crossref","unstructured":"Gardoni, F, Morari, M, Kulisevsky, J, Brugnoli, A, Novello, S, Pisan\u00f2, CA, et al.. Safinamide modulates striatal glutamatergic signaling in a rat model of levodopa-induced dyskinesia. J\u00a0Pharmacol Exp Therapeut 2018;367:442\u201351. https:\/\/doi.org\/10.1124\/jpet.118.251645.","DOI":"10.1124\/jpet.118.251645"},{"key":"2026082508572973721_j_dmdi-2026-0021_ref_049","doi-asserted-by":"crossref","unstructured":"Leuratti, C, Sardina, M, Ventura, P, Assandri, A, M\u00fcller, M, Brunner, M. Disposition and metabolism of safinamide, a novel drug for Parkinson\u2019s disease, in healthy male volunteers. Pharmacology 2013;92:207\u201316. https:\/\/doi.org\/10.1159\/000354805.","DOI":"10.1159\/000354805"},{"key":"2026082508572973721_j_dmdi-2026-0021_ref_050","unstructured":"Electronic Medicines Compendium (emc). Safinamide 100\u00a0mg film-coated tablets: summary of product characteristics (SmPC) [Internet]; 2025. [updated 2025 Nov 24; cited 2026 Jun 25]. Available from: https:\/\/www.medicines.org.uk\/emc\/product\/101655\/smpc."},{"key":"2026082508572973721_j_dmdi-2026-0021_ref_051","doi-asserted-by":"crossref","unstructured":"Abbruzzese, G, Barone, P, Lopiano, L, Stocchi, F. The current evidence for the use of safinamide for the treatment of Parkinson\u2019s disease. Drug Des Dev Ther 2021;15:2507\u201317. https:\/\/doi.org\/10.2147\/dddt.s302673.","DOI":"10.2147\/DDDT.S302673"},{"key":"2026082508572973721_j_dmdi-2026-0021_ref_052","doi-asserted-by":"crossref","unstructured":"Zhang, LG, Cheng, J, An, MQ, Li, CJ, Dong, LG, Wang, JM, et al.. Safinamide alleviates hyperalgesia via inhibiting hyperexcitability of DRG neurons in a mouse model of Parkinson\u2019s disease. Behav Brain Res 2024;459:114787. https:\/\/doi.org\/10.1016\/j.bbr.2023.114787.","DOI":"10.1016\/j.bbr.2023.114787"},{"key":"2026082508572973721_j_dmdi-2026-0021_ref_053","doi-asserted-by":"crossref","unstructured":"Stocchi, F, Antonini, A, Berg, D, Bergmans, B, Jost, W, Katzenschlager, R, et al.. Safinamide in the treatment pathway of Parkinson\u2019s disease: a European Delphi consensus. npj Parkinson\u2019s Dis 2022;8:17. https:\/\/doi.org\/10.1038\/s41531-022-00277-z.","DOI":"10.1038\/s41531-022-00277-z"},{"key":"2026082508572973721_j_dmdi-2026-0021_ref_054","doi-asserted-by":"crossref","unstructured":"Fabbri, M, Rosa, MM, Abreu, D, Ferreira, JJ. Clinical pharmacology review of safinamide for the treatment of Parkinson\u2019s disease. Neurodegener Dis Manag 2015;5:481\u201396. https:\/\/doi.org\/10.2217\/nmt.15.46.","DOI":"10.2217\/nmt.15.46"},{"key":"2026082508572973721_j_dmdi-2026-0021_ref_055","doi-asserted-by":"crossref","unstructured":"Bette, S, Shpiner, DS, Singer, C, Moore, H. Safinamide in the management of patients with Parkinson\u2019s disease not stabilized on levodopa: a review of the current clinical evidence. Therapeut Clin Risk Manag 2018;14:1737\u201345. https:\/\/doi.org\/10.2147\/tcrm.s139545.","DOI":"10.2147\/TCRM.S139545"},{"key":"2026082508572973721_j_dmdi-2026-0021_ref_056","doi-asserted-by":"crossref","unstructured":"Goel, F, Singh, P, Rai, SN, Yadav, DK. Nrf2\/Keap1 signaling axis in the brain: master regulator of oxidative stress in neurodegenerative and psychiatric disorders. Mol Neurobiol 2026;63:197. https:\/\/doi.org\/10.1007\/s12035-025-05517-w.","DOI":"10.1007\/s12035-025-05517-w"},{"key":"2026082508572973721_j_dmdi-2026-0021_ref_057","doi-asserted-by":"crossref","unstructured":"Goel, F, Kumar, D, Singh, P, Rai, SN, Yadav, DK. Molecular crosstalk between miRNAs and lncRNAs in neurodegenerative disease pathways. Mol Biol Rep 2026;53:16. https:\/\/doi.org\/10.1007\/s11033-025-11187-7.","DOI":"10.1007\/s11033-025-11187-7"},{"key":"2026082508572973721_j_dmdi-2026-0021_ref_058","doi-asserted-by":"crossref","unstructured":"Pagonabarraga, J, Tinazzi, M, Caccia, C, Jost, WH. The role of glutamatergic neurotransmission in the motor and non-motor symptoms in Parkinson\u2019s disease: clinical cases and a review of the literature. J\u00a0Clin Neurosci 2021;90:178\u201383. https:\/\/doi.org\/10.1016\/j.jocn.2021.05.056.","DOI":"10.1016\/j.jocn.2021.05.056"},{"key":"2026082508572973721_j_dmdi-2026-0021_ref_059","doi-asserted-by":"crossref","unstructured":"Desaphy, JF, Farinato, A, Altamura, C, De Bellis, M, Imbrici, P, Tarantino, N, et al.. Safinamide\u2019s potential in treating nondystrophic myotonias: inhibition of skeletal muscle voltage-gated sodium channels and skeletal muscle hyperexcitability in\u00a0vitro and in\u00a0vivo. Exp Neurol 2020;328:113287. https:\/\/doi.org\/10.1016\/j.expneurol.2020.113287.","DOI":"10.1016\/j.expneurol.2020.113287"},{"key":"2026082508572973721_j_dmdi-2026-0021_ref_060","doi-asserted-by":"crossref","unstructured":"Desaphy, JF, De Bellis, M, Farinato, A, Altamura, C, Imbrici, P, Caccia, C, et al.. Safinamide effects on skeletal muscle sodium channels and models of non-dystrophic myotonia (NDM) compared to mexiletine: exploring potential for clinical utility. J\u00a0Neurol Sci 2019;405:10. https:\/\/doi.org\/10.1016\/j.jns.2019.10.435.","DOI":"10.1016\/j.jns.2019.10.435"},{"key":"2026082508572973721_j_dmdi-2026-0021_ref_061","doi-asserted-by":"crossref","unstructured":"Sciaccaluga, M, Mazzocchetti, P, Bastioli, G, Ghiglieri, V, Cardinale, A, Mosci, P, et al.. Effects of safinamide on the glutamatergic striatal network in experimental Parkinson\u2019s disease. Neuropharmacology 2020;170:108024. https:\/\/doi.org\/10.1016\/j.neuropharm.2020.108024.","DOI":"10.1016\/j.neuropharm.2020.108024"},{"key":"2026082508572973721_j_dmdi-2026-0021_ref_062","doi-asserted-by":"crossref","unstructured":"Pisan\u00f2, CA, Brugnoli, A, Novello, S, Caccia, C, Keywood, C, Melloni, E, et al.. Safinamide inhibits in\u00a0vivo glutamate release in a rat model of Parkinson\u2019s disease. Neuropharmacology 2020;167:108006. https:\/\/doi.org\/10.1016\/j.neuropharm.2020.108006.","DOI":"10.1016\/j.neuropharm.2020.108006"},{"key":"2026082508572973721_j_dmdi-2026-0021_ref_063","doi-asserted-by":"crossref","unstructured":"Morari, M, Brugnoli, A, Pisan\u00f2, CA, Novello, S, Caccia, C, Melloni, E, et al.. Safinamide differentially modulates in\u00a0vivo glutamate and GABA release in the rat hippocampus and basal ganglia. J\u00a0Pharmacol Exp Therapeut 2018;364:198\u2013206. https:\/\/doi.org\/10.1124\/jpet.117.245100.","DOI":"10.1124\/jpet.117.245100"},{"key":"2026082508572973721_j_dmdi-2026-0021_ref_064","doi-asserted-by":"crossref","unstructured":"Iseppon, F, Kanellopoulos, AH, Tian, N, Zhou, J, Caan, G, Chiozzi, R, et al.. Sodium channels Nav1.7, Nav1.8 and pain; two distinct mechanisms for Nav1.7 null analgesia. Neurobiol Pain 2024;16:100168. https:\/\/doi.org\/10.1016\/j.ynpai.2024.100168.","DOI":"10.1016\/j.ynpai.2024.100168"},{"key":"2026082508572973721_j_dmdi-2026-0021_ref_065","doi-asserted-by":"crossref","unstructured":"Wu, Q, Huang, J, Fan, X, Wang, K, Jin, X, Huang, G, et al.. Structural mapping of Nav1.7 antagonists. Nat Commun 2023;14:3224. https:\/\/doi.org\/10.1038\/s41467-023-38942-3.","DOI":"10.1038\/s41467-023-38942-3"},{"key":"2026082508572973721_j_dmdi-2026-0021_ref_066","doi-asserted-by":"crossref","unstructured":"Alborghetti, M, Bianchini, E, De Carolis, L, Galli, S, Pontieri, FE, Rinaldi, D. Type-B monoamine oxidase inhibitors in neurological diseases: clinical applications based on preclinical findings. Neural Regen Res 2024;19:16\u201321. https:\/\/doi.org\/10.4103\/1673-5374.375299.","DOI":"10.4103\/1673-5374.375299"},{"key":"2026082508572973721_j_dmdi-2026-0021_ref_067","doi-asserted-by":"crossref","unstructured":"Rinaldi, D, Alborghetti, M, Bianchini, E, Sforza, M, Galli, S, Pontieri, FE. Monoamine-oxidase type B inhibitors and cognitive functions in Parkinson\u2019s disease: beyond the primary mechanism of action. Curr Neuropharmacol 2023;21:1214\u201323. https:\/\/doi.org\/10.2174\/1570159x20666220905102144.","DOI":"10.2174\/1570159X20666220905102144"},{"key":"2026082508572973721_j_dmdi-2026-0021_ref_069","doi-asserted-by":"crossref","unstructured":"Guerra, A, Suppa, A, D\u2019Onofrio, V, Di Stasio, F, Asci, F, Fabbrini, G, et al.. Abnormal cortical facilitation and L-dopa-induced dyskinesia in Parkinson\u2019s disease. Brain Stimul 2019;12:1517\u201325. https:\/\/doi.org\/10.1016\/j.brs.2019.06.012.","DOI":"10.1016\/j.brs.2019.06.012"},{"key":"2026082508572973721_j_dmdi-2026-0021_ref_070","doi-asserted-by":"crossref","unstructured":"Bonuccelli, U. Effects of safinamide on motor complications and pain in advancing Parkinson\u2019s disease: post hoc analyses of pivotal trials. Eur Neurol Rev 2015;10:176\u201381. https:\/\/doi.org\/10.17925\/enr.2015.10.02.176.","DOI":"10.17925\/ENR.2015.10.02.176"},{"key":"2026082508572973721_j_dmdi-2026-0021_ref_068","doi-asserted-by":"crossref","unstructured":"Kogo, Y, Koebis, M, Kobayashi, Y, Ishida, T, Maeda, T. Analgesic effect of safinamide mesylate in a rat model of neuropathic pain. Behav Brain Res 2023;452:114555. https:\/\/doi.org\/10.1016\/j.bbr.2023.114555.","DOI":"10.1016\/j.bbr.2023.114555"},{"key":"2026082508572973721_j_dmdi-2026-0021_ref_071","doi-asserted-by":"crossref","unstructured":"Espinoza-Vinces, C, Villino-Rodr\u00edguez, R, Atorrasagasti-Villar, A, Mart\u00ed-Andr\u00e9s, G, Luquin, MR. Impact of safinamide on patient-reported outcomes in Parkinson\u2019s disease. Patient Relat Outcome Meas 2023;14:285\u201395. https:\/\/doi.org\/10.2147\/prom.s369590.","DOI":"10.2147\/PROM.S369590"},{"key":"2026082508572973721_j_dmdi-2026-0021_ref_072","unstructured":"Singh, AK, Rai, SN, editors. Rejuvenating the brain: nutraceuticals, autophagy, and longevity. Singapore: Springer; 2025."},{"key":"2026082508572973721_j_dmdi-2026-0021_ref_073","doi-asserted-by":"crossref","unstructured":"Canfora, I, Altamura, C, Desaphy, JF, Boccanegra, B, Vailati, S, Caccia, C, et al.. Preclinical study of the antimyotonic efficacy of safinamide in the myotonic mouse model. Neurotherapeutics 2024;21:e00455. https:\/\/doi.org\/10.1016\/j.neurot.2024.e00455.","DOI":"10.1016\/j.neurot.2024.e00455"},{"key":"2026082508572973721_j_dmdi-2026-0021_ref_074","doi-asserted-by":"crossref","unstructured":"Hung, TY, Wu, SN, Huang, CW. Safinamide, an inhibitor of monoamine oxidase, modulates the magnitude, gating, and hysteresis of sodium ion current. BMC Pharmacol Toxicol 2024;25:17. https:\/\/doi.org\/10.1186\/s40360-024-00739-5.","DOI":"10.1186\/s40360-024-00739-5"},{"key":"2026082508572973721_j_dmdi-2026-0021_ref_075","doi-asserted-by":"crossref","unstructured":"Santos Garc\u00eda, D, Y\u00e1\u00f1ez Ba\u00f1a, R, Labandeira Guerra, C, Cimas Hernando, MI, Cabo L\u00f3pez, I, Paz Gonz\u00e1lez, JM, et al.. Pain improvement in Parkinson\u2019s disease patients treated with safinamide: results from the SAFINONMOTOR study. J\u00a0Personalized Med 2021;11:798. https:\/\/doi.org\/10.3390\/jpm11080798.","DOI":"10.3390\/jpm11080798"},{"key":"2026082508572973721_j_dmdi-2026-0021_ref_076","doi-asserted-by":"crossref","unstructured":"Cattaneo, C, Kulisevsky, J, Tubazio, V, Castellani, P. Long-term efficacy of safinamide on Parkinson\u2019s disease chronic pain. Adv Ther 2018;35:515\u201322. https:\/\/doi.org\/10.1007\/s12325-018-0687-z.","DOI":"10.1007\/s12325-018-0687-z"},{"key":"2026082508572973721_j_dmdi-2026-0021_ref_077","doi-asserted-by":"crossref","unstructured":"Tsuboi, Y, Koebis, M, Kogo, Y, Ishida, T, Suzuki, I, Nomoto, M, et al.. Effects of safinamide adjunct therapy on pain in patients with Parkinson\u2019s disease: post hoc analysis of a Japanese phase 2\/3 study. J\u00a0Neurol Sci 2021;429:118070. https:\/\/doi.org\/10.1016\/j.jns.2021.118070.","DOI":"10.1016\/j.jns.2021.118070"},{"key":"2026082508572973721_j_dmdi-2026-0021_ref_078","doi-asserted-by":"crossref","unstructured":"Abilashimova, D, Aubakirova, M, Abdildin, Y, Viderman, D. Safinamide for pain management in patients with Parkinson\u2019s disease. Rev Neurol (Paris) 2025;181:11\u201320. https:\/\/doi.org\/10.1016\/j.neurol.2023.10.013.","DOI":"10.1016\/j.neurol.2023.10.013"},{"key":"2026082508572973721_j_dmdi-2026-0021_ref_079","doi-asserted-by":"crossref","unstructured":"Geroin, C, Di Vico, IA, Squintani, G, Segatti, A, Bovi, T, Tinazzi, M. Effects of safinamide on pain in Parkinson\u2019s disease with motor fluctuations: an exploratory study. J\u00a0Neural Transm 2020;127:1143\u201352. https:\/\/doi.org\/10.1007\/s00702-020-02218-7.","DOI":"10.1007\/s00702-020-02218-7"},{"key":"2026082508572973721_j_dmdi-2026-0021_ref_080","doi-asserted-by":"crossref","unstructured":"Cattaneo, C, Barone, P, Bonizzoni, E, Sardina, M. Effects of safinamide on pain in fluctuating Parkinson\u2019s disease patients: a post-hoc analysis. J\u00a0Parkinsons Dis 2017;7:95\u2013101. https:\/\/doi.org\/10.3233\/jpd-160911.","DOI":"10.3233\/JPD-160911"},{"key":"2026082508572973721_j_dmdi-2026-0021_ref_081","doi-asserted-by":"crossref","unstructured":"Chaudhuri, KR, Rizos, A, Trenkwalder, C, Rascol, O, Pal, S, Martino, D, et al.. King\u2019s Parkinson\u2019s disease pain scale, the first scale for pain in PD: an international validation. Mov Disord 2015;30:1623\u201331. https:\/\/doi.org\/10.1002\/mds.26270.","DOI":"10.1002\/mds.26270"},{"key":"2026082508572973721_j_dmdi-2026-0021_ref_082","doi-asserted-by":"crossref","unstructured":"Martinez-Martin, P, Rojo-Abuin, JM, Rizos, A, Rodriguez-Blazquez, C, Trenkwalder, C, Perkins, L, et al.. Distribution and impact on quality of life of the pain modalities assessed by the King\u2019s Parkinson\u2019s disease pain scale. npj Parkinson\u2019s Dis 2017;3:8.","DOI":"10.1038\/s41531-017-0009-1"},{"key":"2026082508572973721_j_dmdi-2026-0021_ref_083","doi-asserted-by":"crossref","unstructured":"Baron, R, Dickenson, AH, Calvo, M, Dib-Hajj, SD, Bennett, DL. Maximizing treatment efficacy through patient stratification in neuropathic pain trials. Nat Rev Neurol 2023;19:53\u201364. https:\/\/doi.org\/10.1038\/s41582-022-00741-7.","DOI":"10.1038\/s41582-022-00741-7"},{"key":"2026082508572973721_j_dmdi-2026-0021_ref_084","doi-asserted-by":"crossref","unstructured":"Jaggi, AS, Jain, V, Singh, N. Animal models of neuropathic pain. Fundam Clin Pharmacol 2011;25:1\u201328. https:\/\/doi.org\/10.1111\/j.1472-8206.2009.00801.x.","DOI":"10.1111\/j.1472-8206.2009.00801.x"},{"key":"2026082508572973721_j_dmdi-2026-0021_ref_085","doi-asserted-by":"crossref","unstructured":"Jali, AM, Banji, D, Banji, OJF, Hurubi, KY, Tawhari, FY, Alameer, AA, et al.. Navigating preclinical models and medications for peripheral neuropathy: a review. Pharmaceuticals 2024;17:1010. https:\/\/doi.org\/10.3390\/ph17081010.","DOI":"10.3390\/ph17081010"},{"key":"2026082508572973721_j_dmdi-2026-0021_ref_086","doi-asserted-by":"crossref","unstructured":"Austin, PJ, Wu, A, Moalem-Taylor, G. Chronic constriction of the sciatic nerve and pain hypersensitivity testing in rats. J\u00a0Vis Exp 2012;3393.","DOI":"10.3791\/3393-v"},{"key":"2026082508572973721_j_dmdi-2026-0021_ref_087","doi-asserted-by":"crossref","unstructured":"Huang, CP, Lin, YW, Lee, DY, Hsieh, CL. Electroacupuncture relieves CCI-induced neuropathic pain involving excitatory and inhibitory neurotransmitters. Evid Based Complement Alternat Med 2019;2019:6784735. https:\/\/doi.org\/10.1155\/2019\/6784735.","DOI":"10.1155\/2019\/6784735"},{"key":"2026082508572973721_j_dmdi-2026-0021_ref_088","doi-asserted-by":"crossref","unstructured":"Tai, YC, Lin, CH. An overview of pain in Parkinson\u2019s disease. Clin Park Relat Disord 2020;2:1\u20138. https:\/\/doi.org\/10.1016\/j.prdoa.2019.11.004.","DOI":"10.1016\/j.prdoa.2019.11.004"},{"key":"2026082508572973721_j_dmdi-2026-0021_ref_089","doi-asserted-by":"crossref","unstructured":"Mylius, V, Lloret, SP, Cury, RG, Teixeira, MJ, Barbosa, VR, Barbosa, ER, et al.. The Parkinson disease pain classification system: results from an international mechanism-based classification approach. Pain 2021;162:1201\u201310. https:\/\/doi.org\/10.1097\/j.pain.0000000000002107.","DOI":"10.1097\/j.pain.0000000000002107"},{"key":"2026082508572973721_j_dmdi-2026-0021_ref_090","doi-asserted-by":"crossref","unstructured":"Fisher, AS, Lanigan, MT, Upton, N, Lione, LA. Preclinical neuropathic pain assessment; the importance of translatability and bidirectional research. Front Pharmacol 2021;11:614990. https:\/\/doi.org\/10.3389\/fphar.2020.614990.","DOI":"10.3389\/fphar.2020.614990"},{"key":"2026082508572973721_j_dmdi-2026-0021_ref_091","doi-asserted-by":"crossref","unstructured":"Grigoriou, S, Mart\u00ednez-Mart\u00edn, P, Ray Chaudhuri, K, Rukavina, K, Leta, V, Hausbrand, D, et al.. Effects of safinamide on pain in patients with fluctuating Parkinson\u2019s disease. Brain Behav 2021;11:e2336. https:\/\/doi.org\/10.1002\/brb3.2336.","DOI":"10.1002\/brb3.2336"},{"key":"2026082508572973721_j_dmdi-2026-0021_ref_092","doi-asserted-by":"crossref","unstructured":"Finnerup, NB, Attal, N, Haroutounian, S, McNicol, E, Baron, R, Dworkin, RH, et al.. Pharmacotherapy for neuropathic pain in adults: a systematic review and meta-analysis. Lancet Neurol 2015;14:162\u201373. https:\/\/doi.org\/10.1016\/s1474-4422(14)70251-0.","DOI":"10.1016\/S1474-4422(14)70251-0"},{"key":"2026082508572973721_j_dmdi-2026-0021_ref_093","doi-asserted-by":"crossref","unstructured":"Fabbri, M, Rosa, MM, Abreu, D, Ferreira, JJ. Clinical pharmacology review of safinamide for the treatment of Parkinson\u2019s disease. Neurodegener Dis Manag 2015;5:481\u201396. https:\/\/doi.org\/10.2217\/nmt.15.46.","DOI":"10.2217\/nmt.15.46"},{"key":"2026082508572973721_j_dmdi-2026-0021_ref_094","doi-asserted-by":"crossref","unstructured":"Aiyer, R, Mehta, N, Gungor, S, Gulati, A. A systematic review of NMDA receptor antagonists for treatment of neuropathic pain in clinical practice. Clin J Pain 2018;34:450\u201367. https:\/\/doi.org\/10.1097\/ajp.0000000000000547.","DOI":"10.1097\/AJP.0000000000000547"},{"key":"2026082508572973721_j_dmdi-2026-0021_ref_095","doi-asserted-by":"crossref","unstructured":"Chogtu, B, Bairy, KL, Smitha, D, Dhar, S, Himabindu, P. Comparison of the efficacy of carbamazepine, gabapentin and lamotrigine for neuropathic pain in rats. Indian J Pharmacol 2011;43:596\u20138. https:\/\/doi.org\/10.4103\/0253-7613.84980.","DOI":"10.4103\/0253-7613.84980"},{"key":"2026082508572973721_j_dmdi-2026-0021_ref_096","doi-asserted-by":"crossref","unstructured":"Seymour, KE, Reinblatt, SP, Benson, L, Carnell, S. Overlapping neurobehavioral circuits in ADHD, obesity, and binge eating: evidence from neuroimaging research. CNS Spectr 2015;20:401\u201311. https:\/\/doi.org\/10.1017\/s1092852915000383.","DOI":"10.1017\/S1092852915000383"},{"key":"2026082508572973721_j_dmdi-2026-0021_ref_097","doi-asserted-by":"crossref","unstructured":"Fitridge, R, editor. Mechanisms of vascular disease: a textbook for vascular specialists, 3rd ed. Cham: Springer; 2020.","DOI":"10.1007\/978-3-030-43683-4"},{"key":"2026082508572973721_j_dmdi-2026-0021_ref_098","unstructured":"Narain, T, Adcock, L. Gabapentin for adults with neuropathic pain: a review of the clinical effectiveness. Ottawa (ON): Canadian Agency for Drugs and Technologies in Health; 2018."},{"key":"2026082508572973721_j_dmdi-2026-0021_ref_099","doi-asserted-by":"crossref","unstructured":"Sadegh, AA, Gehr, NL, Finnerup, NB. A systematic review and meta-analysis of randomized controlled head-to-head trials of recommended drugs for neuropathic pain. Pain Rep 2024;9:e1138. https:\/\/doi.org\/10.1097\/pr9.0000000000001138.","DOI":"10.1097\/PR9.0000000000001138"},{"key":"2026082508572973721_j_dmdi-2026-0021_ref_110","doi-asserted-by":"crossref","unstructured":"Gilron, I, Max, MB. Combination pharmacotherapy for neuropathic pain: current evidence and future directions. Expert Rev Neurother 2005;5:823\u201330. https:\/\/doi.org\/10.1586\/14737175.5.6.823.","DOI":"10.1586\/14737175.5.6.823"},{"key":"2026082508572973721_j_dmdi-2026-0021_ref_111","doi-asserted-by":"crossref","unstructured":"Wasan, H, Singh, D, Kh, R. Safinamide in neurological disorders and beyond: evidence from preclinical and clinical studies. Brain Res Bull 2021;168:165\u201377. https:\/\/doi.org\/10.1016\/j.brainresbull.2020.12.018.","DOI":"10.1016\/j.brainresbull.2020.12.018"},{"key":"2026082508572973721_j_dmdi-2026-0021_ref_112","doi-asserted-by":"crossref","unstructured":"Tsuboi, Y, Hattori, N, Yamamoto, A, Sasagawa, Y, Nomoto, M, ME2125-4 Study Group. Long-term safety and efficacy of safinamide as add-on therapy in levodopa-treated Japanese patients with Parkinson\u2019s disease with wearing-off: results of an open-label study. J\u00a0Neurol Sci 2020;416:117012. https:\/\/doi.org\/10.1016\/j.jns.2020.117012.","DOI":"10.1016\/j.jns.2020.117012"},{"key":"2026082508572973721_j_dmdi-2026-0021_ref_113","doi-asserted-by":"crossref","unstructured":"Cattaneo, C, La Ferla, R, Bonizzoni, E, Sardina, M. Long-term effects of safinamide on dyskinesia in mid-to late-stage Parkinson\u2019s disease: a post-hoc analysis. J\u00a0Parkinsons Dis 2015;5:475\u201381. https:\/\/doi.org\/10.3233\/jpd-150569.","DOI":"10.3233\/JPD-150569"},{"key":"2026082508572973721_j_dmdi-2026-0021_ref_100","unstructured":"U.S. Food and Drug Administration. XADAGO (safinamide) tablets, for oral use: prescribing information [Internet]. Silver Spring (MD): U.S. Food and Drug Administration; 2017. [cited 2026 Jun 26]. Available from: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2017\/207145lbl.pdf."},{"key":"2026082508572973721_j_dmdi-2026-0021_ref_101","doi-asserted-by":"crossref","unstructured":"Perez-Lloret, S, Rascol, O. The safety and efficacy of safinamide mesylate for the treatment of Parkinson\u2019s disease. Expert Rev Neurother 2016;16:245\u201358. https:\/\/doi.org\/10.1586\/14737175.2016.1150783.","DOI":"10.1586\/14737175.2016.1150783"},{"key":"2026082508572973721_j_dmdi-2026-0021_ref_102","unstructured":"Maan, JS, Duong, TH, Saadabadi, A. Carbamazepine [Internet]. In: StatPearls. Treasure Island (FL). StatPearls Publishing; 2026. [updated 2023 Jul 10; cited 2026 Aug 8]. Available from: https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK482455\/."},{"key":"2026082508572973721_j_dmdi-2026-0021_ref_103","doi-asserted-by":"crossref","unstructured":"Di Stefano, G, Truini, A, Cruccu, G. Current and innovative pharmacological options to treat typical and atypical trigeminal neuralgia. Drugs 2018;78:1433\u201342. https:\/\/doi.org\/10.1007\/s40265-018-0964-9.","DOI":"10.1007\/s40265-018-0964-9"},{"key":"2026082508572973721_j_dmdi-2026-0021_ref_104","unstructured":"Beecham, GB, Nessel, TA, Goyal, A. Lidocaine [Internet]. In: StatPearls. Treasure Island (FL). StatPearls Publishing; 2026. [updated 2024 Aug 16; cited 2026 Aug 8]. Available from: https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK539881\/."},{"key":"2026082508572973721_j_dmdi-2026-0021_ref_105","unstructured":"Health Products Regulatory Authority (HPRA). Xadago 50\u00a0mg film-coated tablets: summary of product characteristics (SmPC) [Internet]. Dublin: HPRA; 2013. [cited 2026 Jun 26]. Available from: https:\/\/assets.hpra.ie\/products\/Human\/25456\/LicenseSPC_PA1189-010-001_16012013082238.pdf."},{"key":"2026082508572973721_j_dmdi-2026-0021_ref_106","unstructured":"Rosenbaum, SB, Gupta, V, Patel, P. Ketamine [Internet]. In: StatPearls. Treasure Island (FL). StatPearls Publishing; 2026. [updated 2024 Jan 30; cited 2026 Aug 8]. Available from: https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK470357\/."},{"key":"2026082508572973721_j_dmdi-2026-0021_ref_107","unstructured":"My Health Toolkit. Intravenous anesthetics for the treatment of chronic pain and psychiatric disorders [Internet]. Columbia (SC): my health toolkit. [cited 2026 Jun 26]. Available from: https:\/\/www.myhealthtoolkitcapital.com\/web\/public\/brands\/medicalpolicy\/external-policies\/intravenous-anesthetics-for-the-treatment-of-chronic-pain-and-psychiatric-disorders\/."},{"key":"2026082508572973721_j_dmdi-2026-0021_ref_108","unstructured":"U.S. Food and Drug Administration. NUCYNTA ER (tapentadol) extended-release tablets, for oral use: prescribing information [Internet]. Silver Spring (MD): U.S. Food and Drug Administration; 2018. [cited 2026 Jun 26]. Available from: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2018\/021487s025lbl.pdf."},{"key":"2026082508572973721_j_dmdi-2026-0021_ref_109","unstructured":"Mayo Clinic. Memantine (oral route) [Internet]. Rochester (MN): Mayo Foundation for Medical Education and Research; 2026. [cited 2026 Jun 26]. Available from: https:\/\/www.mayoclinic.org\/drugs-supplements\/memantine-oral-route\/description\/drg-20067012."},{"key":"2026082508572973721_j_dmdi-2026-0021_ref_114","doi-asserted-by":"crossref","unstructured":"Baker, DE, Kim, AP. Formulary drug review: safinamide. Hosp Pharm 2017;52:532\u201343. https:\/\/doi.org\/10.1177\/0018578717726046.","DOI":"10.1177\/0018578717726046"},{"key":"2026082508572973721_j_dmdi-2026-0021_ref_115","doi-asserted-by":"crossref","unstructured":"P\u00e9rez-Torre, P, L\u00f3pez-Send\u00f3n, JL, Ma\u00f1anes Barral, V, Parees, I, Fanjul-Arb\u00f3s, S, Monreal, E, et al.. Concomitant treatment with safinamide and antidepressant drugs: safety data from real clinical practice. Neurologia 2024;39:340\u20134. https:\/\/doi.org\/10.1016\/j.nrleng.2021.08.005.","DOI":"10.1016\/j.nrl.2021.08.004"},{"key":"#cr-split#-2026082508572973721_j_dmdi-2026-0021_ref_116.1","unstructured":"Safinamide. LiverTox: Clinical and Research Information on Drug-Induced Liver Injury [Internet]. Bethesda (MD): National Institute of Diabetes and Digestive and Kidney Diseases. 2012- [updated 2019 Apr 8"},{"key":"#cr-split#-2026082508572973721_j_dmdi-2026-0021_ref_116.2","unstructured":"cited 2026 Aug 8]. Available from: https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK548819\/."},{"key":"2026082508572973721_j_dmdi-2026-0021_ref_117","doi-asserted-by":"crossref","unstructured":"Amir, R, Argoff, CE, Bennett, GJ, Cummins, TR, Durieux, ME, Gerner, P, et al.. The role of sodium channels in chronic inflammatory and neuropathic pain. J\u00a0Pain 2006;7:S1\u201329. https:\/\/doi.org\/10.1016\/j.jpain.2006.01.444.","DOI":"10.1016\/j.jpain.2006.01.444"},{"key":"2026082508572973721_j_dmdi-2026-0021_ref_118","doi-asserted-by":"crossref","unstructured":"LeResche, L. Defining gender disparities in pain management. Clin Orthop Relat Res 2011;469:1871\u20137. https:\/\/doi.org\/10.1007\/s11999-010-1759-9.","DOI":"10.1007\/s11999-010-1759-9"},{"key":"2026082508572973721_j_dmdi-2026-0021_ref_119","doi-asserted-by":"crossref","unstructured":"Paller, CJ, Campbell, CM, Edwards, RR, Dobs, AS. Sex-based differences in pain perception and treatment. Pain Med 2009;10:289\u201399. https:\/\/doi.org\/10.1111\/j.1526-4637.2008.00558.x.","DOI":"10.1111\/j.1526-4637.2008.00558.x"},{"key":"2026082508572973721_j_dmdi-2026-0021_ref_120","doi-asserted-by":"crossref","unstructured":"Sharaf, J, Williams, KAD, Tariq, M, Acharekar, MV, Guerrero Saldivia, SE, Unnikrishnan, S, et al.. The efficacy of safinamide in the management of Parkinson\u2019s disease: a systematic review. Cureus 2022;14:e29118. https:\/\/doi.org\/10.7759\/cureus.29118.","DOI":"10.7759\/cureus.29118"},{"key":"2026082508572973721_j_dmdi-2026-0021_ref_121","unstructured":"Rai, SN, Singh, P, Goel, F. Medicinal plants in Parkinson\u2019s therapy. Academic Press; 2025."},{"key":"2026082508572973721_j_dmdi-2026-0021_ref_122","doi-asserted-by":"crossref","unstructured":"Yuan, JH, Cheng, X, Matsuura, E, Higuchi, Y, Ando, M, Hashiguchi, A, et al.. Genetic, electrophysiological, and pathological studies on patients with SCN9A-related pain disorders. J\u00a0Peripher Nerv Syst 2023;28:597\u2013607. https:\/\/doi.org\/10.1111\/jns.12590.","DOI":"10.1111\/jns.12590"},{"key":"2026082508572973721_j_dmdi-2026-0021_ref_123","unstructured":"Hisama, FM, Dib-Hajj, SD, Waxman, SG. SCN9A neuropathic pain syndromes [Internet]. In: Adam, MP, Bick, S, Mirzaa, GM, et al.., editors. GeneReviews. Seattle (WA): University of Washington, Seattle; 1993-2026. [updated 2020 Jan 23; cited 2026 Aug 8]. Available from: https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK1163\/."},{"key":"2026082508572973721_j_dmdi-2026-0021_ref_124","doi-asserted-by":"crossref","unstructured":"Mian, MU, Afzal, M, Butt, AA, Ijaz, M, Khalil, K, Abbasi, M, et al.. Neuropharmacology of neuropathic pain: a systematic review. Cureus 2024;16:e69028. https:\/\/doi.org\/10.7759\/cureus.69028.","DOI":"10.7759\/cureus.69028"},{"key":"2026082508572973721_j_dmdi-2026-0021_ref_125","doi-asserted-by":"crossref","unstructured":"Bernatoniene, J, Sciupokas, A, Kopustinskiene, DM, Petrikonis, K. Novel drug targets and emerging pharmacotherapies in neuropathic pain. Pharmaceutics 2023;15:1799. https:\/\/doi.org\/10.3390\/pharmaceutics15071799.","DOI":"10.3390\/pharmaceutics15071799"},{"key":"2026082508572973721_j_dmdi-2026-0021_ref_126","doi-asserted-by":"crossref","unstructured":"Chen, R, Liu, Y, Qian, L, Yi, M, Yin, H, Wang, S, et al.. Sodium channels as a new target for pain treatment. Front Pharmacol 2025;16:1573254. https:\/\/doi.org\/10.3389\/fphar.2025.1573254.","DOI":"10.3389\/fphar.2025.1573254"},{"key":"2026082508572973721_j_dmdi-2026-0021_ref_127","doi-asserted-by":"crossref","unstructured":"Fu, Y, Sun, L, Zhu, F, Xia, W, Wen, T, Xia, R, et al.. Ectopic expression of Nav1.7 in spinal dorsal horn neurons induced by NGF contributes to neuropathic pain in a mouse spinal cord injury model. Front Mol Neurosci 2023;16:1091096. https:\/\/doi.org\/10.3389\/fnmol.2023.1091096.","DOI":"10.3389\/fnmol.2023.1091096"},{"key":"2026082508572973721_j_dmdi-2026-0021_ref_128","doi-asserted-by":"crossref","unstructured":"Kitano, Y, Shinozuka, T. Inhibition of NaV1.7: the possibility of ideal analgesics. RSC Med Chem 2022;13:895\u2013920. https:\/\/doi.org\/10.1039\/d2md00081d.","DOI":"10.1039\/D2MD00081D"},{"key":"2026082508572973721_j_dmdi-2026-0021_ref_129","doi-asserted-by":"crossref","unstructured":"Dormer, A, Narayanan, M, Schentag, J, Achinko, D, Norman, E, Kerrigan, J, et al.. A review of the therapeutic targeting of SCN9A and Nav1.7 for pain relief in current human clinical trials. J\u00a0Pain Res 2023;16:1487\u201398. https:\/\/doi.org\/10.2147\/jpr.s388896.","DOI":"10.2147\/JPR.S388896"},{"key":"2026082508572973721_j_dmdi-2026-0021_ref_130","doi-asserted-by":"crossref","unstructured":"Labau, JIR, Estacion, M, Tanaka, BS, de Greef, BTA, Hoeijmakers, JGJ, Geerts, M, et al.. Differential effect of lacosamide on Nav1.7 variants from responsive and non-responsive patients with small fibre neuropathy. Brain 2020;143:771\u201382. https:\/\/doi.org\/10.1093\/brain\/awaa016.","DOI":"10.1093\/brain\/awaa016"},{"key":"2026082508572973721_j_dmdi-2026-0021_ref_131","doi-asserted-by":"crossref","unstructured":"Yang, Y, Mis, MA, Estacion, M, Dib-Hajj, SD, Waxman, SG. NaV1.7 as a pharmacogenomic target for pain: moving toward precision medicine. Trends Pharmacol Sci 2018;39:258\u201375. https:\/\/doi.org\/10.1016\/j.tips.2017.11.010.","DOI":"10.1016\/j.tips.2017.11.010"},{"key":"2026082508572973721_j_dmdi-2026-0021_ref_132","doi-asserted-by":"crossref","unstructured":"Gomez, K, Stratton, HJ, Duran, P, Loya, S, Tang, C, Calderon-Rivera, A, et al.. Identification and targeting of a unique NaV1.7 domain driving chronic pain. Proc Natl Acad Sci U S A 2023;120:e2217800120. https:\/\/doi.org\/10.1073\/pnas.2217800120.","DOI":"10.1073\/pnas.2217800120"},{"key":"2026082508572973721_j_dmdi-2026-0021_ref_133","doi-asserted-by":"crossref","unstructured":"Themistocleous, AC, Crombez, G, Baskozos, G, Bennett, DL. Using stratified medicine to understand, diagnose, and treat neuropathic pain. Pain 2018;159:S31\u201342. https:\/\/doi.org\/10.1097\/j.pain.0000000000001301.","DOI":"10.1097\/j.pain.0000000000001301"},{"key":"2026082508572973721_j_dmdi-2026-0021_ref_134","doi-asserted-by":"crossref","unstructured":"Jost, WH. A critical appraisal of MAO-B inhibitors in the treatment of Parkinson\u2019s disease. J\u00a0Neural Transm 2022;129:723\u201336. https:\/\/doi.org\/10.1007\/s00702-022-02465-w.","DOI":"10.1007\/s00702-022-02465-w"},{"key":"2026082508572973721_j_dmdi-2026-0021_ref_135","doi-asserted-by":"crossref","unstructured":"Alborghetti, M, Nicoletti, F. Different generations of type-B monoamine oxidase inhibitors in Parkinson\u2019s disease: from bench to bedside. Curr Neuropharmacol 2019;17:861\u201373. https:\/\/doi.org\/10.2174\/1570159x16666180830100754.","DOI":"10.2174\/1570159X16666180830100754"}],"container-title":["Drug Metabolism and Personalized Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.degruyterbrill.com\/document\/doi\/10.1515\/dmpt-2026-0021\/xml","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.degruyterbrill.com\/document\/doi\/10.1515\/dmpt-2026-0021\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,25]],"date-time":"2026-08-25T08:57:51Z","timestamp":1787648271000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.degruyterbrill.com\/document\/doi\/10.1515\/dmpt-2026-0021\/html"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,26]]},"references-count":136,"alternative-id":["10.1515\/dmpt-2026-0021"],"URL":"https:\/\/doi.org\/10.1515\/dmpt-2026-0021","relation":{},"ISSN":["2363-8915"],"issn-type":[{"value":"2363-8915","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,26]]}}}